Trial of SAGE-217 in Patients with Major Depressive Disorder. Reply
N Engl J Med
.
2019 Nov 28;381(22):2179.
doi: 10.1056/NEJMc1913170.
Authors
Handan Gunduz-Bruce
1
,
Stephen J Kanes
1
,
Charles F Zorumski
2
Affiliations
1
Sage Therapeutics, Cambridge, MA handan.gunduz-bruce@sagerx.com.
2
Washington University School of Medicine, St. Louis, MO.
PMID:
31774969
DOI:
10.1056/NEJMc1913170
No abstract available
Publication types
Letter
Comment
MeSH terms
Depressive Disorder, Major*
Humans
Psychiatric Status Rating Scales